BackImmuneering Overview
Immuneering Corp - Ordinary Shares Class A

Immuneering Target Price

See Immuneering's analyst price targets ($16) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$4.46

Average Target Price

$15.50247.5% upside

2 analysts in the last 4 months

High: $17 | Low: $14

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-06UBS$14213.9% upsideOpen
2026-07-08Cantor FitzgeraldLi Watsek$17281.2% upsideOpen
2026-03-09Piper Sandler$12169.1% upsideOpen
2025-10-29Mizuho Securities$12169.1% upsideOpen
2025-09-25OppenheimerJay Olson$30572.6% upsideOpen
2024-04-02Mizuho SecuritiesGraig Suvannavejh$879.4% upsideOpen
2024-03-15JefferiesMichael Yee$332.7% downsideOpen
2022-09-30Piper SandlerSwapnil Malekar$41819.3% upsideOpen
2022-07-09Loop Capital MarketsGeulah Livshits$18303.6% upsideOpen

Immuneering (IMRX) FAQ

Immuneering posts a target price of $16. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $16 for IMRX means covering analysts, on average, see the stock 247.5% upside of $4.46 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for IMRX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Immuneering's other metric pages and overview cover the third.

Judging Immuneering against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $16 here, then scan peer and history charts to see if the gap is persistent.